Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488513 · ClinicalTrials.gov registry record · Phase 1
ABC294640 in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by RedHill Biopharma Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01488513 is a Phase 1 study that has completed, run by RedHill Biopharma Limited. The registered enrollment target is 22 participants.
The verdict
NCT01488513, a Phase 1 study, has completed, sponsored by RedHill Biopharma Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of ABC294640 in treating patients with advanced solid tumors. ABC294640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Please note that the FDA OOPD is participating as a funding source.
Interventions
- DRUG sphingosine kinase-2 inhibitor ABC294640
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-08 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01488513
The ClinicalTrials.gov registry entry for NCT01488513 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RedHill Biopharma Limited, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sphingosine kinase-2 inhibitor ABC294640 is the first listed.
NCT01488513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01488513 about?
NCT01488513 is a clinical study titled "ABC294640 in Treating Patients With Advanced Solid Tumors". This phase I trial studies the side effects and best dose of ABC294640 in treating patients with advanced solid tumors. ABC294640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Please note that the FDA OOPD is participating as a funding source.
What is the current status of trial NCT01488513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-08. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01488513?
The interventions under investigation include: sphingosine kinase-2 inhibitor ABC294640 (DRUG).
Who is sponsoring clinical trial NCT01488513?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.